Connection

Besim Ogretmen to Xenograft Model Antitumor Assays

This is a "connection" page, showing publications Besim Ogretmen has written about Xenograft Model Antitumor Assays.
  1. Balance between senescence and apoptosis is regulated by telomere damage-induced association between p16 and caspase-3. J Biol Chem. 2018 06 22; 293(25):9784-9800.
    View in: PubMed
    Score: 0.143
  2. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med. 2013 01; 5(1):105-21.
    View in: PubMed
    Score: 0.098
  3. Potent antitumor activity of a novel cationic pyridinium-ceramide alone or in combination with gemcitabine against human head and neck squamous cell carcinomas in vitro and in vivo. J Pharmacol Exp Ther. 2006 Jun; 317(3):1188-99.
    View in: PubMed
    Score: 0.061
  4. Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma. Nat Commun. 2019 03 21; 10(1):1296.
    View in: PubMed
    Score: 0.038
  5. Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma. Blood. 2014 Sep 18; 124(12):1915-25.
    View in: PubMed
    Score: 0.028
  6. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest. 2013 Oct; 123(10):4144-57.
    View in: PubMed
    Score: 0.026
  7. PERK-dependent regulation of ceramide synthase 6 and thioredoxin play a key role in mda-7/IL-24-induced killing of primary human glioblastoma multiforme cells. Cancer Res. 2010 Feb 01; 70(3):1120-9.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.